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Radiation therapy (RT) induces immunogenic cell death
and dose-dependent release of ATP in the tumor microen-
vironment (TME), triggering maturation and activation of
tumor-resident dendritic cells (DCs). However, extracellu-
lar ATP is rapidly catabolized to adenosine by ectonucleo-
tidases CD39 and CD73, which are expressed by tumor
cells and immune cells in the TME. Adenosine has pleio-
tropic immunosuppressive effects and inhibits activation
of DC and effector T cells, while promoting regulatory
T cells (Tregs). Here, we tested the hypothesis that con-
version of ATP to adenosine hinders generation of effec-
tive anti-tumor immunity by high dose RT, reducing its
synergy with anti-CTLA-4 antibody.
BALB/c mice were inoculated s.c. with 1 x 105 TSA car-
cinoma cells on day 0 and assigned to treatment with: (1)
control mAb; (2) anti-CD73 (TY/23); (3) TY/23+anti-
CTLA-4 (9H10); (4) RT; (5) RT+TY/23; (6) RT+9H10; (6)
RT+TY/23+9H10. TY/23 (200 µg) was administered i.p.
every 4 days starting on day 11. RT was given locally as
single 20 Gy dose on day 12. 9H10 (200 µg) was given i.p.
on days 11, 14 and 17. On day 18, some tumors were har-
vested for flow cytometry analysis of DC and T cells. Mice
were monitored for tumor growth/regression.
In irradiated tumors, CD73-blockade reduced the per-
centage of Tregs within the tumor-infiltrating CD4+ T cell
population (7.9±2.5% in RT+TY/23 vs 20±0.8% in RT, p <
0.01) while increasing CD8+T cells (38.3±0.1% in RT+TY/
23 vs 17.3±4% in RT, p < 0.05). Among intratumoral DCs
(CD11c+MHCII+), the CD8a+ DC subpopulation was
increased after CD73-blockade (37.9±15.7% in TY/23+RT
vs 11.3±4.9% in RT, p < 0.01). Importantly, in irradiated
mice, TY/23-administration enhanced activation of DCs
and effector T cells, shown by increased CD40 expression
on CD8a+ DCs (MFI: 218±1 in RT+TY/23 vs 54±41 in
RT, p < 0.05) and increased CD69 expression on CD8+
T cells (MFI: 513±126 in RT+TY/23 vs 148±59 in RT, p <
0.01). TY/23 and 9H10 given alone or in combination had
no effect on tumor growth. However, each antibody
potentiated tumor inhibition obtained with RT (p=0.08 for
RT+TY/23 and p < 0.05 for RT+9H10 vs RT). Moreover,
blockade of both CD73 and CTLA-4 in combination with
RT further improved tumor control resulting in complete
tumor regression in 2/5 mice (p < 0.01 for RT+TY/23+
9H10 vs RT).
Our findings indicate that adenosine regulates the
ability of RT to induce anti-tumor immunity, affecting
both DC maturation and T cell activation. Data suggest
that CD73-blockade is a promising strategy to improve
synergy of RT and immunotherapy.
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